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Abstract
Aims/hypothesis The protocols used for the preparation of
human pancreatic islets immediately induce a sustained and
massive activation of the c-Jun-N-terminal kinase (JNK).
JNK, which participates in apoptosis of insulin-secreting
cells, is activated by mechanical stresses, as well as by
exposure to pro-inflammatory cytokines. Here, we investigat-
ed whether the delivery of a protease-resistant JNK inhibitory
peptide (D-JNKI) through a protein transduction system
during pancreatic digestion might impair JNK signalling
throughout the transplantation procedure.
Methods Rat pancreases were treated with D-JNKI through
the pancreatic duct and cells then isolated by enzymatic
digestion. Protein extracts were prepared to determine JNK
activity by kinase assays and total RNA was extracted to
measure gene expressions by a Light-Cycler technique. Cell
apoptosis rate was determined by terminal deoxynucleo-
tidyl transferase dUTP nick end labelling (TUNEL) assay
and by scoring cells displaying pycnotic nuclei.
Results Our data establish that the peptide transduction
system used here efficiently transfects islets, allowing for
stable in vivo (up to 2 days) transfection of human islets
transplanted under the kidney capsule. Further, D-JNKI
decreases intracellular JNK signalling during isolation and
following cytokine exposure in both human and rat islets,
as measured by kinase assays and reduced c-fos expression;
D-JNKI also confers protection against apoptosis induced
during the rat islet preparation and subsequent to IL-1β
exposure.
Conclusions/interpretation JNK signalling participates in
islet isolation- and IL-1β-induced apoptosis in rat islets.
Furthermore, the system we used might be more generally
applicable for the persistent blockage (several days) of pro-
apoptotic pathways in the transplanted islets; this days-long
protection might potentially be an absolute prerequisite to
help transplanted islets better survive the first wave of the
non-specific inflammatory attack.
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Introduction
It is estimated that up to 60% of pancreatic islet tissue
undergoes apoptosis within a few days after transplantation,
suggesting that non-specific inflammatory events play a key
role in the destruction of the graft after transplantation [1].
The pro-inflammatory cytokines IL-1β, TNF-α and IFN-γ
participate in the functional impairment and destruction of
beta cells during type 1 diabetes mellitus [2], and are also at
least in part responsible for the observed loss of functional
islet mass (FIM) following grafting [3]. Amongst the three
cytokines, IL-1β is the most important inflammatory
mediator that causes pancreatic islet dysfunction and
destruction [4]. IL-1β alone is sufficient to induce
apoptosis of pancreatic beta cells in both rat and mouse
pancreatic islets, while addition of IFN-γ to IL-1β is
required to trigger apoptosis of human pancreatic islets [5].
In beta cell lines, IL-1β acts mostly by increasing the
activity of two main pathways: the c-Jun N-terminal kinase
(JNK, also known as mitogen-activated protein kinase 8)
[6], and translocation of nuclear factor-kappaB (NF-κB)
[7]. In addition to cytokine stimulation, stress conditions such
as the islet isolation procedure itself also decrease the viability
of pancreatic islets and alter their function with a major loss
occurring shortly after the final purification steps [8].
Both effects, stress conditions during isolation and non-
specific inflammatory events following transplantation,
then combine to strongly impair viability of islets.
Consequently, a high number of islets from multiple donors
are required to perform islet grafting [9], and therefore islet
shortage and early loss of FIM are the main limitations to
the expansion of islet transplantation as a curative therapy
for type 1 diabetes mellitus [10].
We have previously shown that the isolation procedure
extremely potently activates the JNK signalling pathway for a
period of time starting from the earliest steps of isolation up to
several hours following purification (i.e. 6–8 h of activation);
the same pathway is also activated by pro-inflammatory
cytokines [11]. We here investigated whether the delivery of
a protease-resistant JNK inhibitory peptide (D-JNKI) via a
protein transduction system can improve viability of rat
pancreatic islets following isolation or cytokine exposure.
Materials and methods
Isolation and culture of rat islets Pancreases from
Sprague–Dawley male rats (Elevage Janvier, Le Genest
Saint Isle, France) weighing 300 g were distended by
intraductal injection of collagenase solution (10 mg/ml in
10 ml final volume; Worthington Biochemical, Lakewood,
NJ, USA) and digestion was performed in a water bath at 37°C
for 30 min with gentle shaking. Fragmented tissue was
washed, collected by centrifugation and islets were separated
on Ficoll (Sigma Aldrich, San Diego, CA, USA) density
gradients. The isolated islets treated with D-JNKI (1 μmol/l)
(Auspep, Parkville, VIC, Australia) or not were cultured in
1640 medium (Gibco BRL Life Technologies, Miami, FL,
USA) supplemented with 10% (vol/vol) fetal calf serum,
penicillin (100 U/ml) (Gibco BRL Life Technologies) and
streptomycin (100μg/ml) (Gibco BRL Life Technologies) in a
5%CO2 humidified atmosphere at 37°C. Cultured islets were
exposed to recombinant mouse IL-1β (280 U/ng, Sigma
Aldrich) at a concentration of 10 ng/ml for 45 min. Animal
experimentation conformed to the Guide for the Care and
Use of Laboratory Animals, formulated by the National
Research Council, 1996, and Swiss law on animal
protection, and was authorised by the Veterinarian Office
of Canton de Vaud (Lausanne, Switzerland).
Isolation and culture of human islets Human islet isolation
was performed as described previously [11], using the method
of Ricordi et al., which combines enzymatic digestion and
mechanical dissociation [12]. Briefly, the pancreas was
distended after injection of 350 ml of an enzyme solution
(Liberase-HI, reconstituted to a final volume of 350 ml in
HBSS; Roche Molecular Biochemicals, Indianapolis, IN,
USA) into the main pancreatic duct, cut into several pieces
and put in a temperature-controlled chamber. The digested
pancreatic cells were collected by centrifugation and washed
before density gradient purification. Purified islets, treated or
not with D-JNKI (10 μmol/l), were cultured in CMRL-1066
medium supplemented with 10% (vol/vol) fetal bovine
serum (Mediatech, Herndon, VA, USA) in a 5% CO2
humidified atmosphere at 37°C. Islets were then exposed
for 45 min to recombinant human IL-1β at a concentration
of 10 ng/ml (50–200 U/ng; R&D systems, Minneapolis,
MN, USA). Isolated rat and human islets were washed with
PBS, then collected by centrifugation and used for protein
and RNA extraction. The human participants’ exemption
code from the institutional review board is 0307M50821.
Transduction of the islets with fluorescein isothiocyanate (FITC)-
labelled D-TAT transporter (D-TAT-FITC) peptide D-TAT-
FITC transporter peptide (Auspep) at a concentration of
1 μmol/l (in 10 ml cold sterile HBSS containing 10 mg/ml
of collagenase) was injected into the rat pancreatic duct
prior to enzymatic digestion and isolated islets were plated
in culture medium at 37°C. The presence of fluorescent
peptide in the islets was assessed by confocal microscopy
(Zeiss confocal laser scanning microscopy; Leica Confocal
software) at different time-points.
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Islet transplantation under the renal capsule of nude
mice Human islets were incubated for 1 h with or without
D-TAT-FITC (1 μmol/l) peptide at 37°C. Nude mice were
anaesthetised by i.p. injection of pentobarbital and a small
incision was made in the body wall in order to exteriorise
the kidney. An incision in the capsule creates a pocket
between capsule and kidney parenchyma. The islet graft
was inserted into the pocket under the capsule. When
grafting was completed, the kidney was eased back into the
body and the back of the skin was closed. Mice were
allowed to recover and the kidney bearing the islet graft
was removed 2 days later for cryostat sections, and
observed for fluorescent green signal by fluorescence
microscopy.
Islet cell lysis, protein kinase assay and gel quantification Islet
pellets were dislodged into cold lysis buffer (20 mmol/l
Tris-acetate, pH 7.0, 0.27 mol/l sucrose, 1 mmol/l EDTA,
1 mmol/l EGTA, 50 mmol/l sodium fluoride, 1% (vol/vol)
Triton X-100, 10 mmol/l ß-glycerophosphate, 1 mmol/l
dithiothreitol [DTT], 10 mmol/l p-nitrophenylphosphate and
antiproteases) and briefly sonicated prior to centrifugation.
Total protein in cell lysates was quantified by the Bradford
method (Bio-Rad Bioassay Kit; Bio-Rad Laboratories,
Basel, Switzerland). Islet protein extracts (40 μg) were
incubated for 3 h at 4°C with 1 μg of the fusion protein
glutathione S-transferase (GST)-c-Jun coupled with glutathi-
one beads. After centrifugation, the beads were washed
twice and then resuspended in 20 μl kinase buffer
(20 mmol/l HEPES, pH 7.5, 20 mmol/l ß-glycerophosphate,
10 mmol/l MgCl2 and 1 mmol/l DTT) and incubated with
1 μl [γ-33P]ATP (111×1012 Bq/mmol) (Amersham Biosci-
ences, Little Chalfont, Bucks, UK) at 30°C for 30 min. The
reactions were terminated by addition of 2×Laemmli
sample buffer (125 mmol/l Tris-HCl, pH 6.8, 4% SDS,
100 mmol/l DTT, 0.02% [wt/vol] Bromophenol Blue, 20%
[vol/vol] glycerol) and samples were boiled for 5 min.
Phosphorylation of substrate proteins was examined after
overnight exposure of polyacrylamide gels to autoradiography
and quantifications were accomplished by Phosphor-Imager
analysis (Molecular Imager FX; Bio-Rad Laboratories).
Measure of mRNA expression by real-time RT-PCR Total
RNA was extracted from isolated islets using a commercial
Kit (RNeasy Mini-kit protocol; Qiagen, Hilden, Germany)
and quantified by spectrophotometry. RNA was reverse
transcribed to cDNA (1 h at 37°C and 10 min at 95°C) using
random primers (Gibco BRL Life Technologies). Aliquots of
the generated cDNAs were used for gene amplifications. We
applied a quantitative real-time RT-PCR technique to measure
gene expressions; this method has been described in detail
(see manufacturer’s literature: Light Cycler; Roche Molecular
Biochemicals). The PCR uses the following primers: rat c-fos,
sense 5′-GCTGACAGATACGCTCCAAG-3′, antisense 5′-
CCTAGATGATGCCGGAAACA-3′; human c-fos, sense 5′-
TGATACACTCCAAGCGGAGAC-3′, antisense 5′-CC
CAGTCTGCTGCATAGAAGG-3′; human tubulin, sense
5′-CCACGTTGGCCAGGCTGGTGTC-3′, antisense 5′-
CTGTGATGAGTTGCTCAGGGTGG-3′; rat tubulin, sense
5′-GGAGGATGCTGCCAATAACT-3′, antisense 5′-
GGTGGTGAGGATGGAATTGT-3′. The PCR products
were further analysed by agarose gel electrophoresis to
confirm the correct length of the amplified products.
Biological effects of D-JNKI Isolated human and rat islets
(30 islets per well) were treated with increasing doses of D-
JNKI (1, 5, 10, 30 and 50 μmol/l) and cultured for 3 days at
37°C. Islets toxicity was assessed by double staining nuclei
of cells with propidium iodide (10 μg/ml) (Sigma Aldrich)
and Hoechst 33342 (25 μg/ml) (Sigma Aldrich), and then
observed under a fluorescence microscope.
Assessment of islet viability Rat islets (600 islets per well),
treated or not with D-JNKI (1 μmol/l), were cultured for
2 days at 37°C and then exposed to continuous stimulation
with IL-1β (10 ng/ml) for 5 days. Islet cells were washed
with PBS, collected by centrifugation and frozen prior to
cryostat sections. Islet sections were processed for terminal
deoxynucleotidyl transferase (TdT) dUTP nick end label-
ling (TUNEL) assay as described in the protocol (Apoptag
Plus Peroxidase In Situ Apoptosis Detection Kit; Chemicon
International, Billerica, MA, USA). Further, a part of the
islet cells was trypsinised in trypsin–EDTA solution for
15 min at 37°C and apoptotic cells were visualised with
Hoechst 33342 (as fragmented pycnotic blue-stained
nuclei) and counted under the fluorescence microscope.
Statistical analysis All experiments were performed a min-
imum of three times with three different donors. All results are
presented as means±SD. Statistical analysis for multiple
comparisons was determined by Student’s t test or one-way
ANOVA. The differences found between the experimental
groups were statistically significant at p<0.05 or p<0.01.
Results
Cellular uptake of D-TAT-FITC peptide into isolated
islets We previously showed that the D-JNKI peptide is
able to enter beta cell lines in culture and thereby to protect
them from IL-1β-induced apoptosis by blocking the
signalling events downstream of JNK [6]. Because rat and
human pancreatic islets are condensed structures compared
with monolayer-cultured cells, we investigated whether
such a peptide could penetrate throughout the islet mass. To
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this end, we coupled an FITC-glycine group to the NH2-
terminus of the ten amino acid transporter peptide derived
from the human immunodeficiency (HIV)–TAT48–57 nucle-
ar factor sequences. D-TAT–FITC peptide (1 μmol/l) was
injected into the rat pancreatic duct prior to pancreatic
tissue digestion. The fluorescent signal was immediately
monitored at the end of the islet preparation, then isolated
islets were cultured for additional times (24, 36 and 48 h).
Cellular uptake of D-TAT–FITC was efficient and still
detected after 2 days of culture (Fig. 1a). No fluorescence
was recorded in the islet control group treated or not with
FITC, which provides evidence that fluorescein alone does
not cross the cell membrane. In parallel, freshly isolated
human islets were incubated with the labelled peptide and
fluorescence signal was detected as previously (Fig. 1b). To
determine the proficiency of the peptide to translocate into
the core of the islets, transduction was assessed by confocal
laser scanning microscopy of live non-fixed islets. Images
were collected at different plans (z-position), showing the
ability of D-TAT–FITC to transduce throughout the entire
islet (Fig. 1c). In conclusion, the labelled peptide efficiently
enters both human and rat islet cells and appears stable for
up to 2 days of culture. We have also used D-JNKI-FITC;
we were not able to document any differences in penetra-
Fig. 1 Transduction of D-TAT-FITC into pancreatic islets. a D-TAT-
FITC peptide (1 μmol/l) was injected into the rat pancreatic duct
before pancreatic digestion and isolated islets were cultured for the
indicated times (24, 36 and 48 h). Control islet groups represent
isolated islets from FITC untreated (Untreated) or treated pancreas
(FITC). b Fresh human islets were incubated with or without the D-
TAT-FITC peptide (1 μmol/l) for the indicated times (24, 36, and
48 h). The control islet group (Untreated) represents untreated islets.
Treated islets were washed and visualised under a fluorescence
microscopy. c Transduction of D-TAT-FITC (1 μmol/l) was assessed
by confocal laser scanning microscopy of live non-fixed rat islets
incubated for 2 days. Pictures were taken at different focal plans.
Fluorescence was analysed by N-step-20 μm, z-position sectional
scanning of islets (10×). Consecutive sections are shown. d Human
islets were incubated for 1 h with or without the D-TAT-FITC peptide
(1 μmol/l), and were transplanted under the left kidney capsule of
nude mice. The kidney bearing the islet grafts was removed at the
indicated times (24, 36 and 48 h) and was sectioned for morphological
examination under a fluorescence microscope. Controls represent no
grafted kidney tissue (Untreated kidney) or no treated islet graft
(Untreated islets). Data are representative of three independent
experiments
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tion and transduction efficiencies between D-TAT and D-
JNKI (data not shown).
D-TAT-FITC peptide remains stable inside islets in vivo We
next investigated the stability of the D-TAT peptide
molecule in a transplantation context (in vivo). Immediately
after islet purification, isolated human islets were incubated
with or without D-TAT-FITC (1 μmol/l), and then trans-
planted under the left kidney capsule of nude mice. The left
kidney bearing the islet grafts was then removed from the
animal body at different times (24, 36 and 48 h), and
cryostat tissue sections were processed and examined under
the microscope. Tissue sections of the right kidney were
used as control group to monitor the autofluorescence of
the kidney tissue. D-TAT-FITC was observed as an intense
fluorescent signal without detectable leakage in the exam-
ined kidneys bearing the islet grafts (Fig. 1d). This
experiment demonstrates that the D-TAT peptide stably
remains inside the treated islets (in vivo) for at least 2 days
after transplantation.
Biological effects of D-JNKI on isolated pancreatic
islets The inhibitor of JNK (D-JNKI), developed from the
minimal conserved 20 amino acid sequence derived from
the entire JNK binding domain (JBD1–280) of islet brain-1
(IB1), was covalently linked to the D-TAT48–57 transporter
[6]. To study the biological effects of D-JNKI, we first
assessed the potential toxicity of D-JNKI on both rat and
human pancreatic islets. To this end, rat and human
pancreatic islets were incubated with or without D-JNKI
(1, 5, 10, 30 and 50 μmol/l) for up to 3 days and were then
stained with the fluorescent dyes propidium iodide and
Hoechst 33342. The combination of both dyes allows
differential staining of nuclei from dead cells (in red) from
ones with an intact membrane (in blue) [13].
Islet viability was impaired in a concentration- and species-
dependent manner. At 1 μmol/l, D-JNKI appears not toxic in
this assay on rat islets; above 5 μmol/l, significant cell-death
occurs (Fig. 2a). Compared with rat, human islets appear
slightly more resistant with no apparent toxicity recorded at
the concentration of 10 μmol/l. However, human islet
viability was affected when islets were treated with concen-
trations >50 μmol/l (Fig. 2b). These data demonstrate that
D-JNKI appears less toxic on human islets than on rat islets,
which may allow testing of higher concentrations to achieve
protective effects.
D-JNKI decreases JNK signalling during islet preparation
and after IL-1β exposure To study the ability of D-JNKI to
modulate the JNK signalling pathway during the islet
isolation procedure and after cytokine exposure, isolated
rat islets were treated with or without D-JNKI (from the
digestion step), and incubated for 2 days. Cultured islets
were then briefly exposed to the cytokine IL-1β. Total
protein extracts were prepared and JNK activity was
measured by kinase assays using GST-c-Jun as substrate.
Fig. 2 Toxicity of D-JNKI on
pancreatic islets. Isolated rat (a)
and (b) human pancreatic islets
were exposed to increasing con-
centrations of D-JNKI as indi-
cated in a (1, 5, 10 μmol/l), and
b (1, 5, 10, 30 and 50 μmol/l)
and incubated at 37°C for up to
3 days. Islets were double
stained with the fluorescent dyes
Hoechst and propidium iodide.
Stained islets were visualised
under a fluorescence micro-
scope. Data are representative of
four independent experiments
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Activity of JNK was high after islet purification and
declined to a low level over 2 days of culture, as previously
reported [11] (Fig. 3a), and treatment of rat islets (prior
isolation) with D-JNKI strongly (60%) reduced JNK
activity after purification. Short-term exposure of the
cultured islets to IL-1β alone increased JNK activity to
the same high level as during the isolation process. D-JNKI
drastically reduced JNK activity (>50%) (Fig. 3a).
Similarly, we investigated the ability of D-JNKI to
inhibit JNK activation after purification in human islets.
Part of the purified islets treated with or without D-JNKI
was cultured for 2 days and exposed to IL-1β. JNK activity
was assessed by kinase assay as described previously. These
experiments indicated that D-JNKI used at 10 μmol/l (but
not at 1 μmol/l) reduced JNK phosphorylation of c-Jun in
purified islets (Fig. 3b). IL-1β increased JNK activity
(fourfold over untreated control), which was reduced in the
D-JNKI-treated islet group. Of note, D-JNKI was less
efficient in preventing JNK activation following cytokine
stimulation despite the high peptide concentration used
(Fig. 3b).
D-JNKI downregulates c-fos expression during rat islet
preparation and after IL-1β exposure c-fos transcription is
positively regulated by the JNK-target ELK1 transcription
factor [14] and its expression was shown to be induced by
IL-1β in pancreatic beta cells [15]; constitutive expression
of the 280 amino acid JNK-inhibitory domain of IB1 in the
βTC-3 cell line decreases its expression [16]. To determine
whether the cell-permeable peptide D-JNKI could interfere
with JNK signalling in vivo, we measured its effect on the
expression of c-fos in rat islets. Islets treated with or
without D-JNKI (prior to pancreatic digestion) were
cultured for 2 days and exposed to IL-1β. Total RNA was
extracted and reversed to cDNA. Quantification and
normalisation to tubulin indicated that c-fos mRNA is high
in purified islets and reaches a low basal level after 2 days
of culture (Fig. 4). Addition of D-JNKI reduced the
expression of c-fos in the immediate post-isolation period
in comparison with untreated islet controls (Fig. 4). In-
creased c-fos mRNA expression was also detected in rat
islets exposed to IL-1β and a single addition of D-JNKI
significantly reduced its expression level (Fig. 4). In rat
islets, D-JNKI was more efficient in reducing c-fos mRNA
after the purification process than after IL-1β stimulation
despite an equal inhibition on JNK activity after both
stresses (Fig. 3a). Further, addition of D-JNKI did not impair
insulin secretion in pancreatic islets (data not shown).
D-JNKI partially protects from islet cell death D-JNKI was
shown to block apoptosis of the insulin-secreting βTC-3
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Fig. 3 D-JNKI efficiently prevents c-Jun phosphorylation in pancre-
atic islets. a Rat islets were treated with or without D-JNKI (1 μmol/l)
(prior to pancreatic digestion), then purified islets were incubated for
2 days before a short stimulation (45 min) with IL-1β (10 ng/ml).
Proteins were extracted and JNK activity was determined by kinase
assay using GST-c-Jun as substrate. The reaction was incubated
30 min at 30°C in the presence of [γ-33P]ATP and stopped by heating
for 10 min in SDS sample buffer. Samples were resolved on 10%
SDS-PAGE and gels were analysed by autoradiography. Protein
phosphorylation was quantified by Phosphor-Imager. b Human islets
were processed as described above for rat islets. Data shown are the
mean of three independent experiments. n=3, means±SD. **p<0.01
for D-JNKI-treated vs untreated islets and for D-JNKI/IL-1β vs IL-1β
islets
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Fig. 4 D-JNKI downregulates c-fos expression in rat pancreatic islets.
Rat pancreases were treated (prior to the digestion step) with or
without D-JNKI (1 μmol/l) and the isolated islets were incubated for
2 days before being exposed for 45 min to IL-1β (10 ng/ml). No
additional exposure to D-JNKI was performed after the initial
treatment of the pancreas. Total RNA was extracted and mRNA
quantification was evaluated by real-time PCR. Tubulin (tub) was
used as a control for normalisation. The data are representative of
three independent experiments. n=3, means±SD. *p<0.01 for D-
JNKI-treated vs untreated islets and for treated D-JNKI/IL-1β vs IL-
1β islets
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cells in response to IL-1β stimulation [6]. To determine
whether D-JNKI could protect rat islets from cytokine-
induced islet apoptosis, pancreatic islets treated with or
without D-JNKI (prior digestion step) were isolated and
cultured for 2 days before being exposed to IL-1β for up to
5 days. Islet viability was assessed by staining islet cells
with propidium iodide and Hoechst 33342, and morpho-
logical changes were visualised under the fluorescence
microscopy (Fig. 5a). Islets apoptosis was further assessed
by the TUNEL assay, which stains fragmented apoptotic
nuclei brown in our assay (Fig. 5b).
A high level of islet cell apoptosis (determined by
TUNEL assay), as well as morphological changes, was
recorded after IL-1β exposure relative to unexposed controls
(Fig. 5). The majority of the islet cells had lost their
spherical and compact structure and debris was seen around
the disintegrating islets compared with those of the control
group without any apparent loss of structure (Fig. 5a).
The number of positive cells in the TUNEL assay was
higher in the untreated purified islet groups and those
exposed to IL-1β compared with the one treated with D-
JNKI (Fig. 5b). The per cent of apoptotic cells measured by
Fig. 5 D-JNKI protects against
IL-1β-induced cell destruction.
a Rat islets were stained with
both of the nuclear dyes Hoechst
and propidium iodide and
visualised under a fluorescence
microscopy. b Rat pancreases
were treated with or without D-
JNKI (1 μmol/l) before the
enzymatic digestion step. After
purification, islets were cultured
for 2 days, then collected by
centrifugation and stored at
–80°C. Frozen cell pellets were
employed for cryostat sections.
Some islets were exposed to
continuous IL-1β stimulation
(10 ng/ml) for 5 days. Apoptotic
cells determined by TUNEL
reaction were stained brown. c
Islets were separated by trypsin-
EDTA and single cells were
stained with Hoechst for scoring
pycnotic nuclei. Data are repre-
sentative of two independent
experiments, each with two rep-
licates, means±SD. *p<0.01 for
D-JNKI/IL-1β- vs IL-1β-treated
islets
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scoring pycnotic nuclei stained in blue also partially
decreased in D-JNKI-treated islets (Fig. 5c).
Discussion
Several factors have been identified as causing islet death
during isolation or shortly after transplantation. These
include: exposure of islets to pro-inflammatory cytokines
during transplantation that results in both immunological
and non-immunological inflammatory responses [17]; dam-
age caused by the isolation procedure itself including
removal of the extracellular matrix, which increases the
vulnerability of islets during clinical islet transplantation [8,
18]; and exposure to pro-inflammatory cytokines released
by infiltrate cells (macrophages) shortly after transplanta-
tion that is recognised as being one mechanism that
mediates primary non-function of the graft [19, 20].
The main common process of all these factors is the
activation of apoptotic signalling pathways [21]. It is
therefore of critical importance to understand the main
pathways leading to islet death during the whole transplan-
tation procedure in order to improve the efficiency of the
process. In vitro studies have shown that cytokine-mediated
beta cell apoptosis essentially involves the activation of the
JNK and NF-κB signalling pathways [6, 22]. JNK is also
known to be activated in response to the islet isolation
procedure itself [11, 23, 24]. Thus, the ability to manipulate
the JNK signalling pathway may be crucial to the
maintenance of a functioning islet cell graft by reducing
apoptosis [24, 25]. Here, we demonstrated that the isolation
process and IL-1β promote activation of JNK to a similar
degree in both human and rat islets. We further report that
inhibition of the JNK pathway by the cell-permeable
inhibitor D-JNKI peptide prevents JNK activation in rat
and human islets and suppresses the expression of the JNK
nuclear target, c-fos mRNA. D-JNKI also improves
viability after isolation and protects rat islets from IL-1β-
induced islet cell death while preserving insulin secretion
(data not shown).
Our data indicate that JNK signalling contributes to the
apoptotic response of islets. Others have previously
demonstrated that additional pro-apoptotic pathways, includ-
ing NF-κB and the p38 kinases, are likely players in beta cell
death as well [22, 26]. Therefore, we believe that activation
of the JNK signalling pathway is likely to be a necessary,
rather than a sufficient, event for the apoptotic response of
islet cells after both isolation and cytokine stresses. Thus,
optimal recovery of islets might require blockage of several
pathways, including the ones mentioned above. Further
experiments will be needed to test whether the addition of
p38 or NF-κB inhibitors might enhance islet viability.
Ultimately, a cocktail of different apoptotic blockers might
become of general use during the islet isolation-transplanta-
tion procedure.
JNK signalling controls the expression of immediate
early genes such as the c-fos and c-Jun transcription factor
family members [6, 27]. One potential mechanism whereby
JNK might control the beta cell death response could
therefore be through transcriptional regulation. The role of
c-fos in apoptosis was suggested in previous studies,
especially those involving neuronal cells [28, 29]. Blocking
the JNK pathway in our studies decreased c-fos mRNA
expression and correspondingly improved islet viability of
IL-1β-treated pancreatic rat islets. In contrast to the
situation with rat islets, IL-1β exposure of human islets
induced neither c-fos mRNA nor apoptosis, but addition of
D-JNKI decreased c-fos mRNA after islet purification.
However, promising data from other groups have also
shown that JNK inhibition improves viability and function
of human islets after grafting [24, 25]. This indicates that
JNK plays a role in human islet death. Again, activation of
p38 and NF-κB are probably the main pathways to block
simultaneously with JNK to better help islets resist both the
isolation and transplantation procedures.
Use of adenoviral vectors as a strategy for gene delivery
is still associated with toxicity [30, 31], and the use of
protein transduction domains derived from viral proteins to
deliver protective molecules into cells is now well accepted
for safer and more efficient delivery. Many protein
transduction domains (PTDs) have been shown to cross
biological membranes and to promote the delivery of
peptides and protein molecules into diverse cell types [6,
32]. The most used PTDs are derived from the homeo-
domain transcription factor Antennapedia and the HIV
transactivator TAT protein. Many studies have shown that
the TAT transduction system is useful for the delivery of
small peptide drugs in isolated pancreatic islets [33], and
has been shown to be much more efficient than viral
transduction [34]. The D-TAT peptide sequence is short (11
amino acids), has low apparent toxicity at the concen-
trations used here [34], and efficiently and rapidly crosses
the cell membranes and promotes the delivery of small
peptides into different pancreatic beta cells as determined
by confocal experiments [6]. Its transduction seems
independent of receptors and transporters. This indepen-
dence from membrane receptors is highly advantageous for
ex vivo delivery of proteins to islet cells. Further, when
used in its D-form, TAT is highly resistant to proteolytic
degradation and less immunogenic compared with the
L-form [35].
We have described here the effective transduction of
isolated rat and human pancreatic islets (ex vivo) in culture
with the D-TAT peptide. Following grafting, delivery of the
peptide appeared restricted to the grafts with no apparent
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leaking phenomenon 2 days after transplantation. This
property is particularly relevant to achieve high local
concentrations of potent anti-apoptotic drugs while minimis-
ing potentially detrimental side-effects on surrounding
tissues. Finally, the system appeared to stably block JNK
for at least 2 days. This feature might be absolutely
necessary to optimally protect islets against the waves of
attacks of the inflammatory reactions in the days following
transplantation.
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